Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
9 p, 627.4 KB Effects of alirocumab on types of myocardial infarction : Insights from the ODYSSEY OUTCOMES trial / White, Harvey D. (Auckland City Hospital) ; Gabriel Steg, P. (Royal Brompton Hospital (Londres)) ; Szarek, Michael (SUNY Downstate Medical Center School of Public Health) ; Bhatt, Deepak L (Harvard Medical School) ; Bittner, Vera A. (University of Alabama at Birmingham) ; Diaz, Rafael (Instituto Cardiovascular de Rosario) ; Edelberg, Jay M. (Sanofi) ; Erglis, Andrejs (University of Latvia) ; Goodman, Shaun G. (University of Toronto) ; Hanotin, Corinne (Sanofi) ; Harrington, Robert A. (Department of Medicine) ; Wouter Jukema, J. (Leiden University Medical Center) ; Lopes, Renato D. (Duke Clinical Research Institute) ; Mahaffey, Kenneth W. (Stanford University School of Medicine) ; Moryusef, Angele (Sanofi) ; Pordy, Robert (Regeneron Pharmaceuticals) ; Roe, Matthew T. (Duke Clinical Research Institute) ; Sritara, Piyamitr (Mahidol University) ; Tricoci, Pierluigi (CSL Behring) ; Zeiher, Andreas Michael (Goethe University) ; Schwartz, Gregory G. (University of Colorado School of Medicine) ; Cequier Fillat, Angel R. (hospital Universitari de Bellvitge) ; Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ; Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ; Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. [...]
2019 - 10.1093/eurheartj/ehz299
European heart journal, Vol. 40 Núm. 33 (january 2019) , p. 2801-2809  
2.
10 p, 396.0 KB Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events : The ODYSSEY OUTCOMES Trial / Szarek, Michael (State University of New York) ; White, Harvey D. (University of Auckland and Green Lane Cardiovascular Services Auckland City Hospital) ; Schwartz, Gregory G. (Division of Cardiology. University of Colorado School of Medicine) ; Alings, Marco (Amphia Ziekenhuis Molengracht) ; Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ; Bittner, Vera A. (University of Alabama at Birmingham) ; Chiang, Chern-En (Taipei Veterans General Hospital and National Yang-Ming University) ; Diaz, Rafael (Instituto Cardiovascular de Rosario) ; Edelberg, Jay M. (Sanofi) ; Goodman, Shaun G. (University of Toronto) ; Hanotin, Corinne (Sanofi) ; Harrington, R.A. (Stanford University) ; Jukema, J.Wouter (Leiden University Medical Center) ; Kimura, Takeshi (Kyoto University Graduate School of Medicine) ; Kiss, Robert Gabor (Magyar Honvédség Egészségügyi Központ) ; Lecorps, Guillaume (Sanofi) ; Mahaffey, Kenneth W. (Stanford University) ; Moryusef, Angèle (Sanofi) ; Pordy, Robert (Regeneron Pharmaceuticals Inc.) ; Roe, Matthew T. (Duke University Medical Center) ; Tricoci, Pierluigi (Duke University Medical Center) ; Xavier, Denis (St. John's Medical College and Research Institute) ; Zeiher, Andreas Michael (Goethe University) ; Steg, Ph Gabriel (Royal Brompton Hospital (Londres)) ; Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ; Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ; Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ; Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ; Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. [...]
2019 - 10.1016/j.jacc.2018.10.039
Journal of the American College of Cardiology, Vol. 73 Núm. 4 (may 2019) , p. 387-396  

Vegeu també: autors amb noms similars
2 Mahaffey, K.W.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.